These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 31315325

  • 1. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
    Panikar V, Joshi SR, Deogaonkar N, Vadgama J, Nasikkar N, Kamat T, Sheikh S, Jain CC, Wagle T.
    J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
    [Abstract] [Full Text] [Related]

  • 2. A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.
    Bhosle D, Indurkar S, Quadri U, Chandekar B.
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702841
    [Abstract] [Full Text] [Related]

  • 3. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
    Lee JY, Cho Y, Lee M, Kim YJ, Lee YH, Lee BW, Cha BS, Kang ES.
    Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ.
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.
    Babar M, Hussain M, Ahmad M, Akhtar L.
    J Ayub Med Coll Abbottabad; 2021 Aug; 33(2):188-191. PubMed ID: 34137526
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY, Zhang N, Chen R, Zhao JG, Yu P.
    J Diabetes Complications; 2015 Aug; 29(8):1295-303. PubMed ID: 26365905
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S, Studiengruppe Dapagliflozin 006.
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors.
    Shimizu N, Ogawa A, Hayashi A, Shichiri M.
    J Diabetes Complications; 2022 Jul; 36(7):108225. PubMed ID: 35690574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.